Letter by Melgari et al Regarding Article, “Ivabradine: Role in the Chronic Heart Failure Armamentarium”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest Psotka and Teerlink’s1 recent review on the role of ivabradine in the treatment of chronic heart failure. A year after the US Food and Drug Administration granted approval for the use of ivabradine to decrease hospitalization from heart failure, the authors have evaluated the results from the major clinical trials on ivabradine. They conclude that, despite the overall superiority of β-blockers in managing heart failure, ivabradine can reduce heart failure hospitalization in selected patients with high resting heart rates (≥75 bpm) and a reduced ejection fraction who are already treated with a maximized guideline-based therapy.
The authors also point …